Product Description
Irinotecan is a type of chemotherapy. It is also known by its brand name Campto. It is a treatment for cancer that started in the bowel (bowel cancer). This includes the colon and back passage (rectum). (Sourced from: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/irinotecan)
Mechanisms of Action: TOP1 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: Fast Track - Pancreatic Cancer *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Adenocarcinoma | Pancreatic Cancer | Oncology Unspecified
Known Adverse Events: Stomatitis | Lymphopenia | Neutropenia | Asthenia | Diarrhea
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czech Republic, Denmark, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, South Korea, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 84
Highest Development Phases
Phase 3: Adenocarcinoma|Esophageal Cancer|Gastrointestinal Cancer|Pancreatic Cancer|Peritoneal Cancer|Small Cell Lung Cancer
Phase 2: Biliary Tract Cancer|Bladder Cancer|Brain Cancer|Breast Cancer|Cholangiocarcinoma|Colorectal Cancer|Embryonal Rhabdomyosarcoma|Glioma|Hepatoblastoma|Hepatocellular Carcinoma|Islet Cell Carcinoma|Neuroblastoma|Neuroendocrine Carcinoma|Neutropenia|Oncology Solid Tumor Unspecified|Osteosarcoma|Pancreatic Ductal Carcinoma|Peripheral Neuroectodermal Tumors, Primitive|Primitive Neuroectodermal Tumors|Rhabdoid Tumor|Rhabdomyosarcoma|Sarcoma, Ewing|Squamous Cell Carcinoma|Wilms Tumor
Phase 1: Appendiceal Cancer|Ataxia Telangiectasia|Bile Duct Cancer|Lyme Disease|Medulloblastoma|Melanoma|Ovarian Cancer|Prostate Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2015-003602-16 | P2 |
Active, not recruiting |
Oncology Solid Tumor Unspecified |
2029-11-30 |
|
| NANT 2021-01 | P2 |
Recruiting |
Neuroblastoma |
2028-12-01 |
|
| LY01610/CT-CHN-304 | P3 |
Recruiting |
Small Cell Lung Cancer |
2028-06-01 |
44% |
| NCI-2023-00373 | P1 |
Recruiting |
Ovarian Cancer|Lyme Disease|Ataxia Telangiectasia|Gastrointestinal Cancer|Cholangiocarcinoma|Breast Cancer|Melanoma|Colorectal Cancer|Prostate Cancer |
2028-01-31 |